Araris Biotech raises CHF 15.2 mio in Seed financing round
06. November 2020
Araris Biotech Ltd has obtained CHF 15.2 million in a Seed financing round from the investors Pureos Bioventures, 4BIO Capital, btov Partners, Redalpine, VI Partners and Schroder Adveq.
Araris Biotech Ltd, a company pioneering antibody-drug conjugate (ADC)-linker technology, intends to use the proceeds to support advancement of lead ADCs into preclinical and clinical development.
Araris Biotech Ltd was advised in all legal matters with regard to the Seed financing round by Bader Gnehm & Partner. The team consisted of Oliver Gnehm (Partner), Denis A. Parvex (Associate) and Thomas Gysin (Associate).
Bader Gnehm & Partner has been repeatedly awarded as top law firm in the area of "Private Equity and Venture Capital".
The press release of Araris Biotech Ltd can be found here: Araris Biotech